Articles tagged with Anemia
Researchers have identified a new drug class that can enhance red blood cell production in anemic patients, potentially treating Diamond-Blackfan anemia and other conditions. The discovery was made by determining how corticosteroids act to increase the production of red blood cell progenitors.
Researchers have discovered a new treatment option for dialysis-related anemia using FG-2216, which increases erythropoietin (EPO) production in both healthy individuals and patients with end-stage renal disease. The study's findings suggest that the kidneys of dialysis patients retain significant EPO production capacity.
A team of researchers has successfully treated beta-thalassemic mice by increasing hepcidin levels, which limits iron overload and markedly reduces anemia. This approach suggests a new therapeutic strategy for patients with beta-thalassemia, potentially mitigating iron overload and anemia.
A mathematical model developed by researchers at Massachusetts General Hospital and Harvard University can predict the risk of anemia in individuals. The model reflects how red blood cells change in size and hemoglobin content during their four-month lifespan, allowing for early detection of iron-deficiency anemia.
A recent study published in Acta Paediatrica found that childhood stroke is a serious condition with significant long-term effects. The study identified the combined effects of oral contraceptives and smoking as major risk factors for childhood stroke, affecting up to 85% of children who survived a stroke.
Researchers found that high erythropoietin levels are associated with increased mortality in older adults. High levels were linked to higher mortality rates independently of other factors, highlighting the hormone's potential prognostic value.
Researchers have discovered that growth hormone controls skeletal muscle development through IGF-1, whereas its effect on nutrient uptake is independent of IGF-1. In contrast, aldosterone promotes vascular injury by inducing expression of the protein PGF in mouse and human blood vessel walls.
Researchers found that weight-based dosing of taribavirin achieves comparable efficacy to ribavirin for treating chronic hepatitis C, with lower rates of anemia. The study suggests a safer alternative for HCV treatment while maintaining efficacy.
A study found that shorter biological marker length, specifically telomere length, was associated with a higher rate of relapse and lower overall survival in patients with severe aplastic anemia receiving immunosuppressive therapy. The results suggest that telomere length may be a risk factor for disease progression.
Researchers at EMBL identified microRNAs MiR144 and MiR451 as crucial regulators of efficient red blood cell formation. These molecules help fine-tune genes involved in haematopoiesis, allowing for stable oxygen transport under challenging conditions.
Researchers will screen thousands of drug candidates for therapeutic benefits in mice, zebra fish, and human cell lines. The goal is to find compounds that can delay or prevent bone marrow failure and cancer in Fanconi anemia patients.
A new study by Johns Hopkins Medicine reveals that black children with chronic kidney disease have more severe anemia than white children, even when treated equally. The research suggests that genetic variations may be at play and could require tailored treatment guidelines.
Researchers have identified small molecules that bind to TrkB, a protein involved in nerve cell survival, and demonstrated their potential in treating neurodegenerative conditions. Additionally, a new compound has been found to prevent anaphylactic shock by targeting the SphK1-S1P pathway, which may lead to the development of new thera...
A study found that 10.2% of patients developed anemia after Roux-en-Y gastric bypass surgery, primarily due to iron deficiency. Patients at increased risk included menstruating females and those with marginal ulcers on endoscopy.
Two scientific teams at Cincinnati Children's Hospital Medical Center are receiving a total of $2.3 million in research funding to continue studies on novel treatments for leukemia and bone marrow failure. The researchers aim to develop new therapeutic strategies targeting CDC42 and FA protein complexes to eliminate leukemia stem cells.
Researchers have developed a new approach to treating cancer using viruses to infect and kill cancer cells. In mice, combining this with standard therapy led to substantial tumor regression and cure. Additionally, modulating VEGF signaling allowed the cells lining tumor blood vessels to be targeted by viruses, suggesting a potential wi...
A recent study identifies the GLRX5 gene as essential for generating iron-sulfur clusters and maintaining normal iron levels in human cells. The protein deficiency leads to sideroblastic anemia by impairing heme biosynthesis and depleting cytosolic iron in red blood cells.
A study has identified two new proteins, MHF1 and MHF2, that are indispensable for the functional integrity of the Fanconi anemia (FA) pathway. The research reveals how these proteins work together to bind to specific DNA structures and prevent or repair DNA interstrand crosslinks, which can lead to cell defects and disease.
Researchers found more-aggressive ESA treatment practices among severely anemic patients led to better outcomes, while aggressive treatment of mildly anemic patients was associated with increased mortality. The study analyzed data from 4,500 U.S. dialysis units and supported guidelines for safer ESA use in end-stage renal disease patie...
A study of 269,717 new hemodialysis patients found that dialysis centers using larger doses of erythropoiesis-stimulating agents (ESAs) in patients with low hematocrit levels had lower mortality rates. Conversely, centers using more frequent iron dosing in higher hematocrit ranges showed increased mortality risk.
Scientists at Duke University have discovered that a genetic alteration linked to a benign enzyme condition protects some hepatitis C patients from developing hemolytic anemia. This finding opens the door to treatment for previously untreatable patients and may also hold the key to preventing anemia in the first place.
Researchers found that darbepoetin alfa had no significant impact on cardiovascular problems or death rates in patients with chronic kidney disease and anemia. However, the study revealed a notable increase in stroke risk among those taking the drug, compared to placebo group members.
A new study shows that anemic patients with myelodysplastic syndromes (MDS) can gain long-term benefits from erythropoietin and a myeloid growth factor, with improved survival rates and overall quality of life compared to those receiving supportive care alone.
Researchers found that house screening reduced mosquito numbers by 49-59% and malaria-related anaemia in children by half. The authors suggest integrating house screening into vector management programs to combat malaria.
Studies suggest that raising hemoglobin levels with erythropoietin can improve exercise tolerance in heart failure patients. However, a large-scale trial is needed to determine if higher Hb targets are associated with adverse cardiovascular events.
A new study published in CMAJ found that anemia in very elderly individuals aged 85 and older is associated with a higher risk of death. The study, which followed 562 participants for five years, found that prevalent anemia at age 85 was linked to increased mortality rates.
Case Western Reserve researchers found that prenatal exposure to Plasmodium falciparum results in parasite tolerance, increasing susceptibility to malaria and anemia in young children. The study identified three groups: sensitized, exposed-not-sensitized, and not-exposed, with the latter group having a higher risk of malaria infection.
A study found that babies exposed to malaria before birth are more susceptible to the disease and anemia, while others develop a tolerant phenotype. This finding has implications for malaria vaccine design and prevention strategies during pregnancy.
Researchers have successfully generated genetically corrected blood cells from skin cells of Fanconi anemia patients using gene therapy and cell reprogramming techniques. This breakthrough could lead to the development of a new treatment for the disease, which affects the bone marrow and causes a lack of white blood cells.
A new study found that anemia in chronic heart failure patients is associated with a significantly increased risk of death and poorer left ventricular function. Researchers analyzed data from 97,699 patients and concluded that optimal treatment of anemia may reduce mortality rates and improve patient outcomes.
The SLC25A38 gene is responsible for congenital sideroblastic anemia, a rare disease characterized by ringed sideroblasts in bone marrow. Researchers identified the causal mutation in zebra fish, showing its role in hemoglobin synthesis.
A new study found that drugs to combat anemia in cancer patients may actually increase the risk of death and serious blood clots. The use of these agents should not be routine therapy unless proven safe and clinically beneficial.
Studies found that partial correction of severe anemia with erythropoietin improves heart structure, while normalization of hemoglobin levels reduces fatigue in kidney disease patients. However, treating to a normal hemoglobin level may cause harm and is not recommended for all patients.
A new study published in PLoS Medicine found that removing user fees for primary health care changed health utilization behavior but did not improve health outcomes among children under 5 years old in Ghana. The study's findings challenge the assumption that free healthcare leads to better health outcomes.
Research found a high prevalence of gluten-sensitive enteropathy (GSE) in patients with iron deficiency anemia of unknown origin. A gluten-free diet improved anemia in GSE patients with mild duodenal lesions, suggesting GSE as a potential cause of iron-deficient anemia.
A Phase I study combining Revlimid and Vidaza found the combination was well-tolerated and had high activity in treating higher-risk myelodysplastic syndromes (MDS). The therapy resulted in a 39% complete response rate and 72% overall response rate among patients.
An analysis of a phase III clinical trial showed that VIDAZA can improve patient responses, achieving an overall response rate of 51% in higher-risk MDS patients. Continued treatment with VIDAZA led to better outcomes for almost half of responders.
Researchers found a potential new cancer risk and path for testing treatments for people with Fanconi anemia. Restoring the FA pathway reverses irregular cell growth in HPV-positive cells and may reduce cancer risk.
A study found that hookworm infections are prevalent among pregnant women in sub-Saharan Africa, linked to lower haemoglobin levels and increased risk of anaemia. The research estimates that over 37 million women of reproductive age are infected with hookworms, highlighting the need for effective deworming treatment policies.
Adding intravenous iron to chemotherapy-induced anemia treatment boosts response rates by up to 50% and reduces treatment duration, according to a new study. Lower doses of darbepoetin alfa also show improved results with the addition of iron therapy.
Anemia of chronic disease could be an adaptive response to inflammatory illness, rather than a disorder. Researchers suggest treating mild to moderate cases to avoid increased mortality from treatment.
Researchers at the University of Utah have developed a rapid test for hepcidin, which helps diagnose anemia related to chronic illness and diseases of iron overload. The test can distinguish between causes of iron overload, enabling doctors to provide more accurate diagnoses.
Researchers at Stanford University School of Medicine have discovered a protein called p53 that responds to disruptions in the cell's protein factories, leading to changes in skin color and causing anemia in mice. The findings may lead to new treatments for bone marrow failure in humans by modulating the levels of p53.
Researchers found that intermittent preventive treatment (IPT) for malaria lowers anaemia prevalence and improves classroom attention in children aged 5-18 years in Western Kenya. The IPT reduced the occurrence of malaria infection by half and lowered anaemia rates among children.
Research published in PLOS Neglected Tropical Diseases found that co-infections of hookworm, schistosomes, and trichuris amplify the risk of anemia in children. The study suggests that combined treatment for some helminth species could reduce anemia burden in helminth-endemic areas.
Researchers discovered a genetic cause for a rare form of inherited iron deficiency anemia, which may provide insights into iron deficiency in the general population and suggest new treatment approaches. The study identified a gene mutation in the TMPRSS6 protein, leading to excessive hepcidin production and impaired iron absorption.
Two studies published in Blood journal provide insights into the regulation of red blood cell production, linking it to the Hls5 gene and thyroid hormone. This knowledge may lead to new treatments for anaemias that don't respond to current hormone therapy.
Patients with breast cancer who developed anemia during chemotherapy had a significantly higher risk of local recurrence compared to those without anemia. Anemia was defined as a serum hemoglobin level below 12 g/dL during chemotherapy, and occurred in 18.2% of patients receiving CMF chemotherapy.
A study published in PLOS Medicine found that Chikungunya virus-infected mothers rarely harm infants early in pregnancy but can cause severe problems, including brain injury, in babies born near the time of delivery. Researchers recommend clinicians monitor babies exposed to chikungunya around delivery for supportive treatment.
Treating anemia with ESAs increases risk of VTE and death among cancer patients, according to a review of phase 3 trials. There was a significantly increased risk (57") of VTE among patients treated with ESA, while the risk of death was higher for ESA-treated patients compared to the control group.
Gas6 protein has proven successful in treating mice with anemia without causing side effects, while reinforcing EPO's effect. This could form the basis for a new treatment for patients where EPO is ineffective.
Researchers discovered that Gas6 protein increases cell signaling in response to Epo treatment, enhancing its therapeutic potential for treating anemia. The study also found that mice deficient in Gas6 have decreased sensitivity to Epo and reduced ability to recover from anemia.
A retrospective study found a link between erythropoiesis-stimulating agents and leukemic transformation in primary myelofibrosis patients. The research confirmed clinical and laboratory variables associated with leukemia development, including specific treatments that increased the risk of leukemic transformation.
A recent study published in the Clinical Journal of the American Society of Nephrology suggests that persistently low hemoglobin levels in dialysis patients increase their risk of death, while fluctuating levels do not. The research used data from nearly 160,000 patients to analyze the effects of hemoglobin variability on mortality rates.
Researchers developed a new indicator, Hb-Var, measuring hemoglobin level stability in dialysis patients, finding it strongly predicts mortality risk. Higher Hb-Var scores associated with increased death rates, even after adjusting for absolute hemoglobin levels and trends.
A new study suggests that a long-acting erythropoiesis-stimulating agent variant of epoetin could be an effective alternative to conventional therapy for treating anaemia in haemodialysis patients. The treatment involves giving the drug every 2 or 4 weeks, which may reduce errors and improve patient quality of life.
Researchers found that EHEC O157:H7 uses a protein structure called the hemorrhagic coli pilus to attach to human intestinal cells. This adhesion enables bacteria to cause severe abdominal cramps and bloody diarrhea, particularly in vulnerable populations such as the young and elderly.
New research on glutaric acidemia type I reveals that young mice are more susceptible to brain damage due to lysine uptake, which can be mitigated with a novel treatment strategy. Mast cells play a role in abdominal aortic aneurysm development, and blocking LAG-3 might enhance cancer vaccine effectiveness.
Researchers found that hair follicles on the head have the potential to become erythropoietin factories, potentially treating EPO-related anemia. This discovery opens doors to a new approach for treating severe anemia associated with kidney failure and chemotherapy.
A study suggests that measuring anemia can be a useful indicator of the burden and control of neglected tropical diseases. Pharmacogenomics, however, still faces limitations in its application for individualized drug dosing based on hereditary factors, according to a review.